BLRX BioLineRx Ltd.

-0.03  -3%
Previous Close 0.88
Open 0.92
Price To book 1.43
Market Cap 52.51M
Shares 61,782,000
Volume 795,726
Short Ratio 0.37
Av. Daily Volume 508,997

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2a trial initiation announced January 17, 2017.
BL-8040 in combination with KEYTRUDA
Pancreatic cancer
Phase 2 initiated September 2016. Partial data due 2H 2017. Full data due 2H 2018.
BL-8040 in combination with KEYTRUDA - COMBAT trial
Pancreatic cancer
Development plans to be released by early 2017.
Gluten sensitivity
Phase 2b initiated August 2015. Interim analysis due in 2018, with top-line results expected in 2019.
Consolidation treatment for AML cancer patients
Phase 2 trial initiated March 2016. Partial data released March 20, 2017 with topline results by the end of 2017 with Phase 2/3 trial to be initiated 2H 2017.
Mobilization and collection of bone marrow stem cells
Phase 2 data released March 2016. Full set of data presented September 8, 2016
Acute myeloid leukemia (AML) cancer relapsed and refractory

Latest News

  1. BioLineRx Makes Regulatory Submission for Trial of BL-8040
  2. BioLineRx Announces Regulatory Submission for Phase 1b Trial of BL-8040 in Combination with Atezolizumab in AML
  3. [$$] BiolineRX Shares Could Triple
  4. BioLineRx to Report First Quarter 2017 Results on May 25, 2017
  5. BioLineRx to Initiate Phase 3 Study with BL-8040 as Novel Stem Cell Mobilization Treatment Following Successful Meeting with FDA
  6. [$$] Four Small Biotechs See Bullish April Stock Buys
  7. BioLineRx Closes $28.75 Million Underwritten Public Offering of its American Depositary Shares
  8. Today's Research Reports on Biotech Stocks to Watch: Bioline RX and Cara Therapeutics
  9. BioLineRx Prices $25 Million Underwritten Public Offering
  10. BioLineRx Announces Underwritten Public Offering of its American Depositary Shares
  11. BioLineRx's AGI-134 to be Presented at AACR 2017
  12. BioLineRx Reports Year End 2016 Financial Results
  13. BioLineRx Announces Acquisition of Agalimmune Ltd. to Accelerate Expansion of Immuno-Oncology Pipeline
  14. BioLineRx Provides Update on Phase 2 Open-Label Study for BL-8040 as Novel Stem Cell Mobilization Treatment
  15. BioLineRx to Report Annual 2016 Results on March 23, 2017
  16. Two Biotech Catalysts To Watch Right Now: Bioline RX Ltd (BLRX) And AMAG Pharmaceuticals, Inc. (AMAG)
  17. BioLineRx to Present at 2017 BIO CEO & Investor Conference in New York on February 14
  18. BioLineRx (BLRX) Starts Cancer Study on BL-8040+Keytruda
  19. BioLineRx Announces Initiation of Immuno-Oncology Phase 2 Study to Investigate Combination of BL-8040 and KEYTRUDA® for Pancreatic Cancer
  20. BioLineRx to Present at Biotech Showcase 2017 Conference in San Francisco